我武生物(300357) - 2025 Q2 - 季度业绩预告

Performance Forecast Summary The company anticipates a year-on-year increase in its 2025 first-half performance, with net profit attributable to shareholders and non-recurring net profit both showing significant growth Net Profit Attributable to Shareholders | Item | Current Reporting Period | Prior Year Period | | :--- | :--- | :--- | | Net Profit Attributable to Shareholders of Listed Company | Profit: CNY 17,000 – 18,500 (10,000) | Profit: CNY 14,923.10 (10,000) | | Year-on-Year Growth | 13.92% - 23.97% | | Net Profit After Deducting Non-Recurring Gains and Losses | Item | Current Reporting Period | Prior Year Period | | :--- | :--- | :--- | | Net Profit After Deducting Non-Recurring Gains and Losses | Profit: CNY 16,550 – 18,050 (10,000) | Profit: CNY 14,150.42 (10,000) | | Year-on-Year Growth | 16.96% - 27.56% | | Analysis of Performance Change Reasons Performance growth is primarily driven by the company's focus on its core business and robust sales of key products, particularly Artemisia pollen allergen sublingual drops and skin prick test solutions - The company consistently focuses on its core business of allergic disease diagnosis and treatment, with performance growth stemming from increased sales revenue of core products[5] Key Product Sales Performance | Product Name | Sales Revenue in Reporting Period (CNY 10,000) | Year-on-Year Growth Rate | | :--- | :--- | :--- | | Dust Mite Drops | 45,465.52 | 10.51% | | Artemisia Pollen Allergen Sublingual Drops | 2,102.05 | 71.37% | | Skin Prick Test Solution | 632.78 | 104.38% | - The rapid growth of Artemisia pollen allergen sublingual drops and skin prick test solutions is primarily attributed to the company's increased market promotion efforts for these products[5] Other Notes and Risk Warning This performance forecast is a preliminary estimate by the financial department, unaudited by an accounting firm, with final data to be disclosed in the official semi-annual report, urging investor caution - The data in this performance forecast is a preliminary estimate by the company's financial department and has not been audited by an accounting firm[4][7] - Specific financial data will be detailed in the company's '2025 Semi-Annual Report,' and investors are advised to be aware of investment risks[7]